Sonnet BioTherapeutics Holdings, Inc.

NasdaqCM:SONN Stock Report

Market Cap: US$8.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sonnet BioTherapeutics Holdings Dividends and Buybacks

Dividend criteria checks 0/6

Sonnet BioTherapeutics Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-90.5%

Buyback Yield

Total Shareholder Yield-90.5%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Oct 04

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Clinical-stage drugs company Sonnet BioTherapeutics (NASDAQ:SONN) said it has received notice from the Nasdaq over regaining compliance with the minimum bid price requirement. The notice was received on Aug. 22. The company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. SONN had met the requirement on Sep. 30. Shares were trading -1.35% pre-market. Source: Press Release
Seeking Alpha • Sep 16

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

In a bid to maintain a Nasdaq's minimum price requirement, Sonnet BioTherapeutics Holdings (NASDAQ:SONN) has announced plans of 1-for-14 reverse stock split of its shares on Friday The stock is slated to begin trading on split adjusted basis from Sept. 19, 2022. SONN shares are up 21% pre-market.
Seeking Alpha • Jul 22

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Sonnet BioTherapeutics (NASDAQ:SONN) said a phase 1b/2a trial of SON-080 was authorized to begin in Australia in patients with persistent chemotherapy-induced peripheral neuropathy (CIPN). Peripheral neuropathy is damage to the nerves outside the brain and spinal cord (peripheral nerves) causing weakness and pain, usually in the hands and feet. It can also affect digestion, urination and circulation. Chemotherapy can also cause peripheral nerve damage in patients. SON-080 is a proprietary version of recombinant human Interleukin-6 (rhIL-6), the company noted in a July 22 press release. The study, dubbed SB211, is aimed to provide safety data compared to previous IL-6 products, along with preliminary efficacy. "Interleukin-6 has been extensively studied in cancer patients in the past, so the use of SON-080 in CIPN is expected to provide similar safety, PK, and PD results at low doses," said Sonnet's Chief Medical Officer Richard Kenney. The company noted that recruitment has begun and dosing is expected to begin imminently.
Analysis Article • Dec 19

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SONN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SONN's dividend payments have been increasing.

Dividend Yield vs Market

Sonnet BioTherapeutics Holdings Dividend Yield vs Market
How does SONN dividend yield compare to the market?
SegmentDividend Yield
Company (SONN)n/a
Market Bottom 25% (US)1.3%
Market Top 25% (US)4.0%
Industry Average (Biotechs)2.1%
Analyst forecast (SONN) (up to 3 years)n/a

Notable Dividend: Unable to evaluate SONN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SONN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate SONN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SONN has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/03 03:53
End of Day Share Price 2025/12/02 00:00
Earnings2025/06/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sonnet BioTherapeutics Holdings, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Keay NakaeChardan Capital Markets, LLC